Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)
May 18, 2020 5:44 PM EDTAfter-Hours Stock Movers:
Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.
Gamida Cell... More
Gossamer Bio Inc. (GOSS) Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
May 18, 2020 4:04 PM EDTGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the notes) in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.
Gossamer also expects to grant the underwriters of the common stock offering a 30-day... More
